| Recruiting | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd NCT07138209 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma NCT07369895 | O&D BioTech Group CO., Limited | Phase 1 |
| Recruiting | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma NCT07018050 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma NCT07312188 | Shandong New Time Pharmaceutical Co., LTD | Phase 2 |
| Not Yet Recruiting | Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy NCT06825845 | CARsgen Therapeutics Co., Ltd. | — |
| Recruiting | A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma NCT06604715 | Janssen Research & Development, LLC | Phase 1 |
| Not Yet Recruiting | A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma NCT06500507 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma NCT06574568 | Excyte Biopharma Ltd | Phase 1 |
| Active Not Recruiting | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myelom NCT06425991 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma NCT06375044 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma NCT06298266 | Guangdong Second Provincial General Hospital | EARLY_Phase 1 |
| Recruiting | A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. NCT06232096 | Beijing Mabworks Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiw NCT06163040 | Bristol-Myers Squibb | — |
| Completed | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in P NCT06055075 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Terminated | Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multipl NCT06068400 | Guangzhou Bio-gene Technology Co., Ltd | N/A |
| Withdrawn | mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05918250 | ModernaTX, Inc. | Phase 1 |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab NCT05927571 | Genentech, Inc. | Phase 1 |
| Unknown | A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma NCT05920876 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma NCT05913804 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Active Not Recruiting | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, NCT05572515 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma NCT05565807 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases NCT05647512 | LaNova Medicines Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib NCT05552976 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amy NCT05652335 | Janssen Research & Development, LLC | Phase 1 |
| Active Not Recruiting | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidom NCT05455320 | Janssen Research & Development, LLC | Phase 3 |
| Withdrawn | Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM NCT05408026 | Alliance Foundation Trials, LLC. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dex NCT05519085 | Celgene | Phase 3 |
| Completed | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma NCT05227144 | ORIC Pharmaceuticals | Phase 1 |
| Active Not Recruiting | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignanci NCT04684108 | Hangzhou Sumgen Biotech Co., Ltd. | Phase 1 |
| Unknown | Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM NCT05052970 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomi NCT04939142 | Antengene Corporation | Phase 3 |
| Completed | A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma NCT05011097 | Wuhan YZY Biopharma Co., Ltd. | Phase 1 |
| Terminated | A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma NCT04735575 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma NCT04706936 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Completed | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma NCT04798586 | Pfizer | Phase 1 |
| Completed | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet NCT04191616 | Amgen | Phase 2 |
| Unknown | CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT04626752 | Hebei Senlang Biotechnology Inc., Ltd. | EARLY_Phase 1 |
| Unknown | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma NCT04194931 | The First Affiliated Hospital of Nanchang University | Phase 1 |
| Terminated | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory NCT03837509 | Incyte Corporation | Phase 1 / Phase 2 |
| Terminated | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, NCT03755154 | Institut de Recherches Internationales Servier | Phase 1 |
| Completed | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone i NCT03859427 | Amgen | Phase 3 |
| Unknown | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma NCT03815383 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 |
| Unknown | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma NCT03751293 | Hebei Yanda Ludaopei Hospital | Phase 1 |
| Completed | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patien NCT03464916 | Sorrento Therapeutics, Inc. | Phase 1 |
| Completed | Selinexor, Cyclophosphamide and Prednisone in Myeloma NCT06212596 | University of Leeds | Phase 2 |
| Terminated | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Communi NCT03512353 | Amgen | Phase 2 |
| Completed | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma NCT02939183 | Amgen | Phase 1 |
| Terminated | AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants Wit NCT02675452 | Amgen | Phase 1 |
| Completed | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) NCT02834364 | University of Heidelberg Medical Center | Phase 2 |
| Completed | Study of BEBT-908 in Subjects With Advanced Hematological Tumors NCT06082596 | BeBetter Med Inc | Phase 1 |
| Terminated | QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma NCT02099539 | Altor BioScience | Phase 1 |
| Completed | Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophospha NCT02046915 | University Hospital Tuebingen | Phase 2 |
| Terminated | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment NCT02075021 | NYU Langone Health | Phase 1 / Phase 2 |
| Completed | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma NCT01866293 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Terminated | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma NCT01670994 | Altor BioScience | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4 NCT01058434 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patien NCT00773838 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bo NCT00708292 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myelom NCT00642954 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previousl NCT00478777 | Celgene Corporation | Phase 3 |
| Completed | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma NCT00545519 | Washington University School of Medicine | Phase 1 |
| Approved For Marketing | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients NCT05463939 | Janssen Research & Development, LLC | — |
| No Longer Available | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma NCT05503550 | Janssen Research & Development, LLC | — |
| Approved For Marketing | Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma NCT05757973 | Janssen Research & Development, LLC | — |